2-piperidone has been researched along with lc15-0444 in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.13) | 29.6817 |
| 2010's | 49 (76.56) | 24.3611 |
| 2020's | 13 (20.31) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JY; Choi, YJ; Hong, JH; Hwang, DM; Jang, IJ; Kim, JA; Kim, JR; Kim, KP; Kwon, OH; Lim, KS; Shin, HS; Shin, KH; Shin, SG; Yu, KS | 1 |
| Cho, JY; Jang, IJ; Kim, BH; Kim, DK; Kim, HS; Kim, JR; Kim, SH; Lee, SH; Lim, KS; Shin, SG; Yim, HJ; Yu, KS | 1 |
| Bae, HY; Baik, SH; Cha, BS; Kim, DK; Kim, JA; Kim, MJ; Kim, SW; Kim, YK; Lee, HW; Lee, IK; Lee, MK; Lee, WY; Min, KW; Park, JY; Park, KS; Rhee, EJ; Yoo, SJ; Yoon, KH | 1 |
| Cho, JY; Jang, IJ; Kim, MJ; Kim, SE; Kim, TE; Kim, YH; Shin, KH; Shin, SG; Yi, S; Yoon, SH; Yu, KS | 1 |
| Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR | 1 |
| Agarwal, PK; Baik, SH; Dharmalingam, M; Gandhi, P; Gupta, SK; Kim, DM; Kim, JA; Kim, PK; Kim, YS; Mahesh, U; Min, KW; Mohan, V; Park, JY; Pitale, SU; Shivane, VK; Sosale, A; Yang, SJ | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Kim, SH; Lee, SH; Yim, HJ | 1 |
| Birks, V; Ford, G; Kim, N; Lee, SH; Mair, S; Patrick, L; Stevens, L | 1 |
| Bae, KS; Choi, HY; Kim, B; Kim, JA; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH | 1 |
| Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS | 1 |
| Kim, EY; Kim, N; Kim, YH; Lee, SH; Oh, MK; Park, SJ; Shin, JG; Shon, JH | 1 |
| Cha, DR; Cha, JJ; Chung, YY; Han, JY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Lee, JE; Lee, MH; Lee, MJ; Min, HS; Song, HK | 1 |
| Kim, DH; Kim, IS; Kim, U; Kim, Y; Lee, J; Lee, SH; Yoo, HH | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Baik, SH; Choi, DS; Choi, HY; Choi, KM; Hong, HC; Hwang, HJ; Jung, TW; Kim, NH; Kim, SG; Ryu, JY; Seo, JA; Yoo, HJ | 1 |
| Bae, KS; Bang, K; Choi, HY; Han, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS | 1 |
| Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS | 1 |
| Cho, MH; Jung, E; Kim, J; Kim, S; Kim, SH | 1 |
| Baik, SH; Choi, DS; Choi, KM; Chung, HS; Hong, HC; Hwang, HJ; Jung, TW; Kim, NH; Kim, SG; Ryu, JY; Seo, JA; Yoo, HJ | 1 |
| Jang, IJ; Jung, JH; Kim, JA; Lee, H; Lim, KS; Oh, J; Park, SI; Yu, KS | 1 |
| Cho, MH; Ho Kim, S; Jung, E; Kim, J; Kim, S | 1 |
| Baek, SH; Kim, JW; Kim, SH; Kim, YJ; Lee, KW; Na, KY | 1 |
| Choi, SH; Lee, IK; Leem, J; Oh, CJ; Park, KG; Park, S | 1 |
| Baik, SH; Choi, DS; Choi, KM; Hong, HC; Hwang, HJ; Jung, TW; Kim, BH; Kim, NH; Kim, SG; Seo, JA; Yoo, HJ | 1 |
| Cheng, XW; Kim, DJ; Kim, SY; Kim, W; Kim, YG; Lee, A; Lee, KH; Lee, SH; Lim, SJ; Moon, JY; Seo, JW; Woo, JS | 1 |
| Chung, BH; Jin, J; Jin, L; Lim, SW; Yang, CW | 1 |
| Hwang, DM; Jung, E; Kim, DW; Kim, J; Kim, SH; Kwon, OH; Lee, SM; Yim, HJ; Yoon, MK | 1 |
| Chamnan, P; Han, KA; Kim, DJ; Kim, ES; Kim, EY; Kim, M; Kim, SH; Kwon, S; Lee, KW; Lee, MK; Lim, S; Moon, MK; Wongtanate, M; Yoon, KH; Yu, J | 1 |
| Ahn, CH; Cho, YM; Kim, EK; Min, SH; Oh, TJ | 1 |
| Choi, SH; Lee, CK; Lee, IK; Leem, J; Park, KG; Park, S | 1 |
| Cha, DR; Han, BG; Han, SY; Jang, YH; Jeong, KH; Jo, YI; Kang, SW; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, SH; Yoon, SA | 1 |
| Ahn, CH; Ahn, KJ; Chung, CH; Han, KA; Jang, HC; Kim, BJ; Kim, CH; Kim, J; Kim, SW; Ko, KP; Lee, DH; Lee, H; Lee, HW; Lee, KJ; Nam, JY; Oh, TK; Park, HK; Park, JH; Park, KS; Park, SW; Park, TS; Yu, JM | 1 |
| Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S | 1 |
| Ihm, CG; Jeong, KH; Kim, DR; Kim, JS; Kim, YG; Lee, SH; Lee, SY; Lee, TW; Moon, JY | 1 |
| Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
| Cho, JH; Choi, JY; Choi, SY; Kim, CD; Kim, YL; Oh, EJ; Park, SH; Ryu, HM | 1 |
| Cha, DR; Han, BG; Han, SY; Jang, Y; Jeong, KH; Jo, YI; Kang, SW; Kim, B; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, S; Yoon, SA | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 3 |
| Choi, SH; Lee, IK; Leem, J | 1 |
| Chung, CH; Jang, HC; Jung, CH; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Cao, L; Li, G; Mohetaer, M; Wang, Y | 1 |
| Bae, JC; Cha, BS; Han, S; Hong, EG; Kim, KA; Kim, YH; Min, KW; Park, CY | 1 |
| Conde-Carmona, I; García-Medina, S; Jiménez-Vargas, JM; Lee, SH; Martínez-Muñoz, A | 1 |
| Bae, KS; Cho, YS; Lee, SH; Lim, HS | 1 |
| Chung, JY; Lee, S; Lee, SW; Park, SI; Yu, KS | 1 |
| Choi, YK; Jung, GS; Jung, YA; Lee, IK; Lee, S; Park, KG; Park, M; Seo, JB; Woo, HI | 1 |
| Benjachareonwong, S; Chamnan, P; Cho, YM; Choi, S; Deerochanawong, C; Kang, ES; Kim, S; Kosachunhanun, N; Kwon, S; Lee, MK; Lee, WJ; Oh, T; Pratipanawatr, T; Sattanon, S; Seekaew, S; Sirirak, T; Suraamornkul, S; Suwanwalaikorn, S | 1 |
| Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC | 1 |
| Bae, J; Cha, BS; Cho, Y; Huh, KH; Joo, DJ; Kang, ES; Kim, MS; Kim, Y; Kim, YS; Lee, BW; Lee, JY; Lee, M; Lee, YH | 1 |
| Jang, IJ; Kim, E; Lee, S; Park, KR; Yu, KS | 1 |
| Baek, KH; Hong, OK; Kim, MK; Kwon, HS; Lee, MK; Lee, SS; Song, KH; Yoo, SJ | 1 |
| Agarwal, PK; Baik, SH; Gupta, SK; K Shivane, V; Kim, DM; Kim, YE; Min, KW; Park, JY; Yang, SJ | 1 |
| Cha, KS; Choi, YS; Kim, DJ; Kim, DK; Kim, EH; Kim, IJ; Kim, SS; Ku, BJ; Lee, CW; Song, KH | 1 |
| Jung, WK; Kang, WS; Kim, HR; Kim, J; Park, SB | 1 |
| Jang, IJ; Lee, S; Yang, E; Yoo, H; Yu, KS | 1 |
| Agarwal, A; Dutta, D; Khandelwal, D; Maisnam, I; Sharma, M; Singla, R | 1 |
| Ahn, BR; Kim, MS; Nguyen, HD; Oh, H; Yoon, IM | 1 |
| Chirananthavat, T; Claimon, T; Sanpatchayapong, A; Satirapoj, B; Suraamornkul, S; Trakarnvanich, T | 1 |
| Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N | 1 |
| Hwang, YJ; Jung, GS; Lee, KM | 1 |
| Chung, SM; Hong, JH; Hwang, IC; Lim, S; Moon, JS | 1 |
3 review(s) available for 2-piperidone and lc15-0444
| Article | Year |
|---|---|
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Piperidones; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system.
Topics: Animals; Bayes Theorem; Humans; Hypoglycemic Agents; Metformin; Piperidones; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
33 trial(s) available for 2-piperidone and lc15-0444
| Article | Year |
|---|---|
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Topics: Adolescent; Adult; Area Under Curve; Blood Glucose; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Glucagon-Like Peptide 1; Half-Life; Humans; Insulin; Korea; Male; Metabolic Clearance Rate; Organic Chemicals; Piperidones; Pyrimidines; Young Adult | 2008 |
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Korea; Male; Metabolic Clearance Rate; Organic Chemicals; Piperidones; Pyrimidines; Young Adult | 2009 |
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Organic Chemicals; Piperidones; Placebos; Pyrimidines; Republic of Korea; Treatment Outcome | 2010 |
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Male; Middle Aged; Organic Chemicals; Pioglitazone; Piperidones; Pyrimidines; Thiazolidinediones; Young Adult | 2012 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Humans; Ketoconazole; Male; Organic Chemicals; Piperidones; Pyrimidines; Republic of Korea; Rifampin; Tandem Mass Spectrometry; Time Factors; Young Adult | 2012 |
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exercise; Fasting; Female; Glycated Hemoglobin; Humans; India; Male; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Risk Reduction Behavior | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Topics: Administration, Oral; Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Feces; Gastrointestinal Absorption; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Piperidones; Protein Binding; Pyrimidines | 2014 |
Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Food-Drug Interactions; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Piperidones; Postprandial Period; Pyrimidines; Republic of Korea; Sex Factors; Tablets; Young Adult | 2014 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Young Adult | 2014 |
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Humans; Hypoglycemic Agents; Male; Piperidones; Pyrimidines; Republic of Korea; Sulfonylurea Compounds; Tandem Mass Spectrometry; Young Adult | 2014 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Irbesartan; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2015 |
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Topics: Adult; Area Under Curve; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Organization and Administration; Piperidones; Pyrimidines; Republic of Korea; Tablets; Therapeutic Equivalency; Young Adult | 2015 |
Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Cisplatin; Clinical Protocols; Creatinine; Cytoprotection; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Piperidones; Prospective Studies; Pyrimidines; Republic of Korea; Research Design; Time Factors; Young Adult | 2015 |
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Piperidones; Proinsulin; Pyrimidines; Republic of Korea; Thailand; Treatment Outcome | 2017 |
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Blood Glucose; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endotoxemia; Endotoxins; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Male; Middle Aged; Piperidones; Postprandial Period; Pyrimidines; RNA, Messenger; Subcutaneous Fat, Abdominal; Transcriptome; Triglycerides; Tumor Necrosis Factor-alpha | 2017 |
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Topics: Aged; Albuminuria; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Treatment Outcome | 2017 |
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Risk; Sulfonylurea Compounds | 2017 |
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2017 |
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Kidney; Linagliptin; Male; Middle Aged; Patient Dropouts; Piperidones; Pyrimidines; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonylurea Compounds | 2018 |
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Treatment Outcome | 2018 |
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium | 2019 |
Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Male; Metformin; Mexico; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2018 |
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Topics: Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Healthy Volunteers; Humans; Male; Metformin; Middle Aged; Patient Safety; Piperidones; Pyrimidines; Tablets; Young Adult | 2018 |
Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Topics: Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Healthy Volunteers; Humans; Metformin; Piperidones; Pyrimidines; Tandem Mass Spectrometry | 2019 |
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Piperidones; Pyrimidines; Treatment Outcome; Weight Gain | 2020 |
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2020 |
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Topics: Adult; Dose-Response Relationship, Drug; Drug Combinations; Healthy Volunteers; Humans; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium; Young Adult | 2019 |
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidones; Pyrimidines | 2021 |
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Neoplasms; Piperidones; Prognosis; Prospective Studies; Pyrimidines; Republic of Korea; Treatment Outcome | 2020 |
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Topics: Adult; Cross-Over Studies; Drug Compounding; Female; Healthy Volunteers; Humans; Male; Middle Aged; Molecular Structure; Piperidones; Pyrimidines; Rosuvastatin Calcium; Tablets | 2021 |
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
Topics: Aged; Alkaline Phosphatase; Ankle Brachial Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Fatty Acid-Binding Proteins; Female; Glomerular Filtration Rate; Hepatitis A Virus Cellular Receptor 1; Humans; Lipocalin-2; Male; Middle Aged; Osteopontin; Piperidones; Pulse Wave Analysis; Pyrimidines; Reactive Oxygen Species; Vascular Calcification | 2021 |
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.
Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Prospective Studies; Pyrimidines; Sulfonylurea Compounds | 2023 |
28 other study(ies) available for 2-piperidone and lc15-0444
| Article | Year |
|---|---|
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Industry; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Piperidones; Pyrimidines; Republic of Korea | 2013 |
Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Topics: Area Under Curve; Creatinine; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Piperidones; Pyrimidines; Renal Dialysis; Renal Insufficiency | 2014 |
Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.
Topics: Animals; Cytokines; Dinoprost; Dipeptidyl-Peptidase IV Inhibitors; Fibrosis; Kidney; Kidney Diseases; Mice; Mice, Inbred C57BL; Oxidative Stress; Piperidones; Proteinuria; Pyrimidines; Statistics, Nonparametric; Ureteral Obstruction | 2014 |
Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
Topics: Administration, Oral; Animals; Bile; Carbon Radioisotopes; Dipeptidyl-Peptidase IV Inhibitors; Feces; Hydroxylation; Inactivation, Metabolic; Intestinal Absorption; Male; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Tissue Distribution | 2014 |
Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes.
Topics: Animals; Apoptosis; Cell Line; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Inflammation; Inflammation Mediators; Models, Biological; Multienzyme Complexes; Myocytes, Cardiac; Phosphorylation; Piperidones; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tunicamycin | 2014 |
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Topics: Animals; Collagen; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosylation; Guanidines; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Piperidones; Pyrimidines; Rats; Serum Albumin, Bovine | 2014 |
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.
Topics: Adenylate Kinase; Cell Adhesion; Cells, Cultured; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; E-Selectin; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Macrophages; Piperidones; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Vascular Cell Adhesion Molecule-1 | 2015 |
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Advanced Oxidation Protein Products; Albuminuria; Animals; Apoptosis; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glomerular Filtration Rate; Guanine; Male; Mice, Inbred C57BL; Piperidones; Podocytes; Protein Serine-Threonine Kinases; Pyrimidines; Receptor for Advanced Glycation End Products | 2015 |
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Topics: Animals; Carotid Artery Injuries; Cell Adhesion Molecules; Cell Movement; Cell Proliferation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; G1 Phase Cell Cycle Checkpoints; HEK293 Cells; Humans; Hyperplasia; Male; Matrix Metalloproteinase 2; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; NF-E2-Related Factor 2; Piperidones; Pyrimidines; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Time Factors; Transfection; Vascular Remodeling | 2015 |
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Topics: AMP-Activated Protein Kinases; Animals; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Hep G2 Cells; Humans; Insulin Resistance; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Piperidones; Pyrimidines | 2015 |
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Topics: Albuminuria; Animals; Apoptosis; Cardiomegaly; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Forkhead Box Protein O3; Forkhead Transcription Factors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunohistochemistry; Kidney; Male; Mice; NADPH Oxidases; Piperidones; Podocytes; Proto-Oncogene Proteins c-akt; Pyrimidines; Ventricular Dysfunction | 2016 |
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Topics: Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Exenatide; Hyperglycemia; Islets of Langerhans; Male; Metformin; Mitochondria; Oxidative Stress; Peptides; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Reactive Oxygen Species; Sirolimus; Venoms | 2016 |
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Kinetics; Male; Mice; Piperidones; Pyrimidines; Rats; Substrate Specificity | 2016 |
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Topics: Adipocytes; Animals; Diet, Western; Fatty Liver; Fibrosis; Hypercholesterolemia; Hypertrophy; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Piperidones; Pyrimidines; Subcutaneous Fat; Uncoupling Protein 1; Weight Gain | 2017 |
Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.
Topics: Acute Kidney Injury; Animals; Apoptosis; Disease Models, Animal; Doxorubicin; Humans; Inflammation; Kidney Diseases; Male; Membrane Proteins; Mice; Oxidative Stress; Piperidones; Pyrimidines; Repressor Proteins; WT1 Proteins | 2017 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
Topics: Adenine; Animals; Aorta, Abdominal; Calcium; Core Binding Factor Alpha 1 Subunit; Dipeptidyl-Peptidase IV Inhibitors; Frizzled Receptors; Gene Expression Regulation; Intercellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidase 4; NADPH Oxidases; Phosphates; Phosphatidylinositol 3-Kinases; Piperidones; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renal Insufficiency, Chronic; Transcription Factor Pit-1; Vascular Calcification; Wnt Signaling Pathway | 2017 |
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Survival; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Flow Cytometry; Humans; Isoxazoles; Piperidones; Pyrimidines; Resorcinols; Signal Transduction; Thyroid Neoplasms | 2017 |
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Cell Survival; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Piperidones; Pyrimidines; Signal Transduction; Sulfonamides; Thyroid Neoplasms; Tumor Cells, Cultured | 2018 |
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Topics: AMP-Activated Protein Kinases; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hypoglycemic Agents; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Potential, Mitochondrial; Metformin; Phosphorylation; Piperidones; Pyrimidines; Signal Transduction; Thyroid Neoplasms; Vascular Cell Adhesion Molecule-1 | 2018 |
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Topics: Animals; Apoptosis; Chemokine CCL2; Cisplatin; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heme Oxygenase-1; Inflammation Mediators; Kidney; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; NAD(P)H Dehydrogenase (Quinone); Piperidones; Protective Agents; Pyrimidines; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2017 |
Protective effects of gemigliptin against type II collagen degradation in human chondrocytes.
Topics: Cartilage, Articular; Cells, Cultured; Chondrocytes; Collagen Type II; Humans; Interleukin-1beta; Metalloendopeptidases; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Piperidones; Protective Agents; Pyrimidines; Signal Transduction | 2018 |
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
Topics: Administration, Oral; Animals; Cell Line; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Fibrosis; Humans; Inflammasomes; Inflammation; Kidney Tubules, Proximal; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Piperidones; Protective Agents; Pyrimidines; Signal Transduction; Transforming Growth Factor beta; Ureteral Obstruction | 2019 |
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Organ Transplantation; Piperidones; Pyrimidines; Retrospective Studies | 2019 |
Gemigliptin Inhibits Interleukin-1β-Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway.
Topics: Bone Morphogenetic Proteins; Epithelial-Mesenchymal Transition; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-1beta; Mesoderm; Piperidones; Pyrimidines; Signal Transduction | 2020 |
Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Apoptosis; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Male; Oxidative Stress; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Reactive Oxygen Species; Salivary Gland Diseases; Salivary Glands; Salivation; Streptozocin | 2021 |
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Topics: Amino Acids; Animals; Benzhydryl Compounds; Choline; Cytokines; Diet, High-Fat; Disease Models, Animal; Disease Progression; Glucosides; Inflammation; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Liver; Macrophage Activation; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphorylation; Piperidones; Protective Agents; Pyrimidines | 2022 |
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.
Topics: Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Doxorubicin; Fibroblast Growth Factors; Humans; Mice; Piperidones; Pyrimidines | 2022 |